Form 4: Cartesian Therapeutics Chief Technology Officer Sells Shares to Cover Tax Obligations

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

Summary

• Metin Kurtoglu, the Chief Technology Officer of Cartesian Therapeutics, sold shares of common stock on January 3, 2025, and January 6, 2025.
• On January 3, 2025, he sold 2,417 shares at a price of $16.7219 per share.
• On January 6, 2025, he sold 2,458 shares at a price of $16.8322 per share.
• These sales were made to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
• Following these transactions, Mr. Kurtoglu beneficially owns 62,258 shares of Cartesian Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for an executive to cover tax obligations, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for them to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar sales by executives at other firms.
• The sale prices are within the normal range for the company's stock price.

Stakeholder Impact

• The stock sales by the Chief Technology Officer may have a minor impact on the stock price, but it is unlikely to be significant given the routine nature of the transaction.

Key Dates

Keywords

Cartesian Therapeutics, Metin Kurtoglu, stock sale, insider trading, restricted stock units, tax obligations, share sale, Form 4